

**S3 Table.** Response rates of patients with recurrent uveal melanoma treated with only first-line systemic therapies (n=27)

	Chemotherapy <sup>a)</sup> (n=26)	Immunotherapy <sup>b)</sup> (n=1)	p-value
<b>Disease control rate (DCR)</b>			
No. (%)	11 (34.6)	0	0.99
95% CI	24.480-59.310	0.000-83.250	
CR	0	0	
PR	0	0	
SD	9	0	
<b>PFS (mo)</b>			
Median	1.93	1.97	0.839
95% CI	1.529-2.331	N/A	
<b>OS2 (mo)</b>			
Median	15.67	3.83	0.033
95% CI	13.260-18.080	N/A	

PFS, progression-free survival (defined to the time interval from the initiation of first-line systemic therapies to the date of documented disease progression or death); OS2, overall survival (defined to the time from recurrence of uveal melanoma to death from any cause); 95% CI, 95% confidence interval; CR, complete response; PR, partial response; SD, stable disease. <sup>a)</sup>Includes dacarbazine, platinum-based regimen, topotecan, <sup>b)</sup>Includes interferon.